McCarthy Consultant Services Regulatory Affairs Consulting for the Healthcare Industry

McCarthy Consultant Services Inc. (MCSI) provides expert regulatory affairs consulting. As a global industry leader, MCSI understands the importance of sound regulatory management and client satisfaction.

Regulatory affairs services for the pharmaceutical and medical industries

Our ability to tackle difficult and complex regulatory issues quickly and efficiently has made MCSI a trusted and valued provider of regulatory affairs services to the biotechnology, pharmaceutical, medical device, natural health product, food and cosmetic industries.

MCSI is considered a major asset by Canadian, foreign and virtual organisations conducting business in Canada, the US and EU. With our regulatory capabilities, we can successfully guide your products through complicated regulations.

MCSI has built worldwide, strategic alliances with organisations, allowing us to offer our clients access to the UK, Australia, Japan, the Nordic countries, Russia and Eastern Europe.

Expert opinions and outsourcing of regulatory affairs

We can provide a range of services, from offering well-established, multinational companies an expert opinion, to outsourcing all regulatory affairs for small startup firms.

Whether it is regulatory strategic planning or a full product submission, MCSI has an expert team of regulatory associates who can get your project completed.

Regulatory affairs and quality assurance services

Along with regulatory strategic planning and preparation and filing of product applications for drugs, medical devices, natural health products, MCSI also offers a wide range of other regulatory affairs and assurance services, including:

  • Preparation of applications for drug establishment licences, medical device establishment licences and site licences
  • Preparation of drug master files
  • GMP design, audits and training
  • SOP writing and training
  • Design and management of quality assurance / quality control systems
  • Validation
  • Due diligence
  • Government liaison

Regulatory and quality assurance projects

MCSI has worked on various regulatory and quality assurance projects, including:

  • New Drug Submissions and New Drug Applications
  • Abbreviated New Drug Submissions and Abbreviated New Drug Applications
  • Supplemental New Drug Submissions and Supplemental New Drug Applications
  • Investigational Testing Application and Investigational New Drug Application
  • Drug Identification Number Applications (DIN)
  • Natural Product Number Applications (NPN)
  • Medical Device License Applications
  • Good manufacturing practices (GMP) system design and management
  • Standard operating procedures (SOP) writing
  • Drug Master Files
  • Rx-to-OTC switches
  • Labeling and advertising review

To discuss your regulatory outsourcing needs, please get in touch with us using the enquiry form below.

Make an enquiry

McCarthy Consultant Services

Unit 8

1151 Gorham Street


L3Y 8Y1



+1 905 836 0033 +1 905 836 0006

McCarthy Consultant Services Images

Products and Services


White Papers

Related Projects

Fasenra (benralizumab) for the Treatment of Asthma

Fasenra (benralizumab) is a monoclonal antibody (mAb) indicated for the treatment of severe eosinophilic asthma in patients aged 12 years and older.

27th March 2018

Zinbryta (daclizumab) for the Treatment of Multiple Sclerosis

Zinbryta (daclizumab) is an injectable formulation jointly developed by Biogen and Abbive for the treatment of relapsing forms of multiple sclerosis (MS) in adults.

22nd March 2018

Austedo (deutetrabenazine) for the Treatment of Chorea Associated with Huntington’s Disease

Austedo™ (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT 2) inhibitor indicated for the treatment of chorea associated with Huntington’s disease.

15th December 2017

Alunbrig (brigatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Alunbrig (brigatinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC).

16th May 2017

Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Paediatric Patients

Dysport (abobotulinumtoxinA) is an injectable formulation developed by Ipsen Biopharmaceuticals for the treatment of lower limb spasticity in paediatric patients aged two years or older.

25th August 2016

Xiidra (lifitegrast ophthalmic solution) for the Treatment of Dry Eye Disease

Xiidra lifitegrast ophthalmic solution is a twice-a-day eye drop solution developed by Shire as a treatment for the signs and symptoms of dry eye disease in adults.

17th July 2016

ONZETRA Xsail for the Treatment of Migraine in Adults

ONZETRA Xsail is a Food and Drug Administration (FDA)-approved intranasal dry powder formulation developed by Avanir Pharmaceuticals.

24th May 2016

Onivyde (irinotecan liposome injection) for the Treatment of Metastatic Pancreatic Cancer

Onivyde (MM-398 / irinotecan liposome injection) is an intravenous injection indicated for the treatment of metastatic pancreatic cancer.

28th October 2015

Press Release

Regional Offices

McCarthy Consultant Services

Unit 8

1151 Gorham Street


L3Y 8Y1



Matt McCarthy +1 905 836 0033 +1 905 836 0006

Go Top